C-CREST = 1 & 2 - Part A, Grazoprevir and MK-8408 with Either Elbasvir or MK-8408 with HCV Geno 1,2, 3 - Alan Franciscus

Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and
Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with
Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1,
2 or 3 Infection (Part A of C-CREST-1 & 2)—E Grane et al.    
Source:  The Liver Conference - Late Breaker 15

Results and Conclusions
The study was to evaluate the safety and efficacy of all-oral therapy of grazoprevir; MK-3682, and either elbasvir or MK-8408.  In Part A of 2 ongoing clinical trial of 93 genotype 1 patients (46 genotype 1a, 47 genotype 1b), 61 genotype 2 patients, and 86 genotype 3 treatment-naïve, non-cirrhotic patients.  The patients were treated for eight weeks with a combination of one of the above medications as a once-a-day dose.

The Bottom Line
The 8-week therapy of grazoprevir/MK-3682 (450 mg)/MK-8408 produced high cure rates in genotypes 1, 2, and 3 treatment naïve patients with mild disease.     

Editorial Comment
Studies are needed in a more diverse patient population, but so far this new combination looks very encouraging.  

Labels: , , , ,